May 24, 2010 | Laboratory News, Laboratory Pathology
Laboratory Corporation of America will also acquire Diamond Reference Laboratory
Last week, financially-troubled Westcliff Medical Laboratories, Inc., of Santa Ana, California, filed a Chapter 11 bankruptcy action in federal court. The news was disclosed to Westcliff clients in a letter signed by Westcliff’s Chairman and CEO. Even as this news became public, Westcliff announced that its assets would be acquired by Laboratory Corporation of America (NYSE: LH), subject to approval by the bankruptcy court.
In a separate transaction, LabCorp is acquiring Diamond Reference Laboratory of Diamond Bar, California. Diamond Reference Laboratory has estimated annual revenue of $10 million. Westcliff Medical Laboratories reported annual revenue of $97 million for 2009. When these two clinical laboratory acquisitions close, LabCorp will have picked up a 5% increase in its share of California’s estimated $2 billion laboratory testing market.
(more…)
May 5, 2010 | Laboratory News, Laboratory Pathology, Management & Operations
Medical laboratory test data represents an essential component of the patient health record
It will soon be the era of patient health records (PHRs), based on data gathered during a survey conducted by the California HealthCare Foundation (CHCF). That has implications for clinical laboratories and pathology groups across the United States, since most laboratories now electronically report laboratory test results to physicians and their patients.
Press coverage of the study, titled “Consumers and Health Information Technology: A National Survey” following its release last month, touted the findings that wealthier individuals tend to use PHRs more, but that those with lower incomes and chronic conditions who use PHRs tend to benefit the most.
(more…)
Apr 30, 2010 | Laboratory Pathology
More multiplex and multi-analyte testing lies ahead for clinical pathology laboratories.
Several experts predict that clinical pathology laboratories will see the use of multiplex assays and multi-analyte diagnoses increase significantly in the near future. As this happens, both the science and the operations of clinical laboratories and pathology practices will grow in sophistication and complexity.
This week at the Executive War College on Laboratory and Pathology Management in New Orleans, Louisiana, almost 600 pathology and laboratory leaders gathered from 12 nations across the globe. During Wednesday’s general session, Thomas M. Grogan, M.D., Founder and Chief Scientific Advisor of Roche Ventana Medical Systems laid out his vision of how surgical pathology will evolve in the future.
(more…)
Apr 7, 2010 | Instruments & Equipment, Laboratory Pathology
Laboratory automation technology is ready and about to move into production
Most large clinical pathology laboratories in the United States and other developed nations now have a decade or more of experience with laboratory automation. In response to what is now a substantial market for laboratory automation, in vitro diagnostics (IVD) manufacturers are preparing to introduce the next generation of laboratory automation.
“Lab automation is a market, particularly in Asia, that has reached what we call mid-level maturity. It is no longer unusual to have an automated laboratory, it’s almost routine. Today, the question is ‘what’s next?’” observed Robin A. Felder, Ph.D. , publisher of Medical Automation and Professor of Pathology and Associate Director of Clinical Chemistry at the University of Virginia in Charlottesville, Virginia.
(more…)
Mar 31, 2010 | Laboratory News, Laboratory Pathology
Pathology labs would generally benefit if Judge Sweet’s ruling is upheld on appeal
It was positive news for many clinical pathology laboratories when a judge ruled against Myriad Genetics and the University of Utah Research Foundation in the federal suit attacking its patents for the BRCA1 and BRCA2 genes. The suit was brought by a group of patients, medical organizations and the American Civil Liberties Union (ACLU).
In Association for Molecular Pathology, et al v. U.S. Patent and Trademark Office 09-civ-4515, pathologist groups, patient advocacy groups, and the American Civil Liberties Union (ACLU) are challenging patents for the BRCA I and BRCA II genes which are held by the University of Utah and licensed exclusively to Myriad Genetics, Inc., (NASDAQ:MYGN) of Salt Lake City, Utah.
(more…)
